Skip to main content

Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension

Clinical Research in Cardiology volume 100, pages 879–885 (2011)Cite this article

Abstract

Soluble TWEAK is a member of the TNF-alpha family of cytokines that has been shown to predict mortality in patients with heart failure. Pulmonary artery hypertension is a devastating disease, in which right ventricular function has been shown to be the major determinant of prognosis. In this hypothesis-generating study, we sought to evaluate the potential usefulness of sTWEAK in the prediction of disease severity in patients with pulmonary artery hypertension. We therefore conducted a retrospective analysis of sTWEAK serum levels in 95 stable patients with PAH. For all patients data on hemodynamic parameters, biomarkers and functional exercise tests were available. Compared to controls, patients with PAH showed significantly decreased levels of sTWEAK [median 314 pg/ml (interquartile range 217–473 pg/ml) vs. 405 (321–496 pg/ml); PAH vs. controls; P < 0.0001]. Soluble TWEAK levels were inversely correlated with NYHA class, pulmonary artery pressure, pulmonary vascular resistance, NT-proBNP, and troponin T levels and directly correlated with cardiac index, reduced 6-min walk test distances, and peak oxygen consumption. ROC curve analysis of sTWEAK levels in PAH patients revealed a cutoff value of 306 pg/ml for sTWEAK to be predictive of a reduced exercise capacity (6-min walk test <300 m) in patients with PAH with a similar predictive value compared to NT-proBNP. Intraindividual serial evaluation of sTWEAK revealed the potential of sTWEAK as follow-up marker in patients with PAH. In our hypothesis-generating study, sTWEAK was closely correlated to hemodynamic, functional, and serological indices of outcome in patients with PAH. Further prospective studies are needed to determine the role of sTWEAK as potential biomarker in patients with PAH.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

43,34 €

Price includes VAT (Finland)
Tax calculation will be finalised during checkout.

Fig. 1
Fig. 2
Fig. 3
Fig. 4

References

  1. Chicheportiche Y, Bourdon PR, Xu H, Hsu YM, Scott H, Hession C, Garcia I, Browning JL (1997) TWEAK, a new secreted ligand in the tumor necrosis factor family that weakly induces apoptosis. J Biol Chem 272:32401–32410

    PubMed  Article  CAS  Google Scholar 

  2. Winkles JA (2008) The TWEAK-Fn14 cytokine-receptor axis: discovery, biology and therapeutic targeting. Nat Rev Drug Discov 7:411–425

    PubMed  Article  CAS  Google Scholar 

  3. Bover LC, Cardó-Vila M, Kuniyasu A, Sun J, Rangel R, Takeya M, Aggarwal BB, Arap W, Pasqualini R (2007) A previously unrecognized protein-protein interaction between TWEAK and CD163: potential biological implications. J Immunol 178:8183–8194

    PubMed  CAS  Google Scholar 

  4. Dogra C, Hall SL, Wedhas N, Linkhart TA, Kumar A (2007) Fibroblast growth factor inducible 14 (Fn14) is required for the expression of myogenic regulatory factors and differentiation of myoblasts into myotubes. Evidence for TWEAK-independent functions of Fn14 during myogenesis. J Biol Chem 282:15000–15010

    PubMed  Article  CAS  Google Scholar 

  5. Chorianopoulos E, Rosenberg M, Zugck C, Wolf J, Katus HA, Frey N (2009) Decreased soluble TWEAK levels predict and adverse prognosis in patients with chronic stable heart failure. Eur J Heart Fail 11:1050–1056

    PubMed  Article  CAS  Google Scholar 

  6. Chorianopoulos E, Jarr K, Steen H, Giannitsis E, Frey N, Katus HA (2010) Soluble TWEAK is markedly upregulated in patients with ST-elevation myocardial infarction and related to an adverse short-term outcome. Atherosclerosis 211:322–326

    PubMed  Article  CAS  Google Scholar 

  7. Richter B, Rychli K, Hohensinner PJ, Berger R, Mörtl D, Neuhold S, Zorn G, Huber K, Maurer G, Wojta J, Pacher R, Hülsmann M, Niessner A (2010) Differences in the predictive value of tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in advanced ischemic and non-ischemic heart failure. Atherosclerosis 213(2):545–548

    PubMed  Article  CAS  Google Scholar 

  8. Chorianopoulos E, Heger T, Lutz M, Frank D, Bea F, Katus HA, Frey N (2010) FGF-inducible 14-kDa protein (Fn14) is regulated via the RhoA/ROCK kinase pathway in cardiomyocytes and mediates nuclear factor-kappaB activation by TWEAK. Basic Res Cardiol 105:301–313

    PubMed  Article  CAS  Google Scholar 

  9. Mustonen E, Säkkinen H, Tokola H, Isopoussu E, Aro J, Leskinen H, Ruskoaho H, Rysä J (2010) Tumour necrosis factor-like weak inducer of apoptosis (TWEAK) and its receptor Fn14 during cardiac remodelling in rats. Acta Physiol (Oxf) 199:11–22

    Article  CAS  Google Scholar 

  10. Jain M, Jakubowski A, Cui L, Shi J, Su L, Bauer M, Guan J, Lim CC, Naito Y, Thompson JS, Sam F, Ambrose C, Parr M, Crowell T, Lincecum JM, Wang MZ, Hsu YM, Zheng TS, Michaelson JS, Liao R, Burkly LCA (2009) Novel role for tumor necrosis factor-like weak inducer of apoptosis (TWEAK) in the development of cardiac dysfunction and failure. Circulation 119:2058–2068

    PubMed  Article  CAS  Google Scholar 

  11. Muñoz-García B, Moreno JA, López-Franco O, Sanz AB, Martín-Ventura JL, Blanco J, Jakubowski A, Burkly LC, Ortiz A, Egido J, Blanco-Colio LM (2009) Tumor necrosis factor-like weak inducer of apoptosis (TWEAK) enhances vascular and renal damage induced by hyperlipidemic diet in ApoE-knockout mice. Arterioscler Thromb Vasc Biol 29:2061–2068

    PubMed  Article  Google Scholar 

  12. Schapira K, Burkly LC, Zheng TS, Wu P, Groeneweg M, Rousch M, Kockx MM, Daemen MJ, Heeneman S (2009) Fn14-Fc fusion protein regulates atherosclerosis in ApoE-/- mice and inhibits macrophage lipid uptake in vitro. Arterioscler Thromb Vasc Biol 29:2021–2027

    PubMed  Article  CAS  Google Scholar 

  13. Galiè N, Hoeper MM, Humbert M, Torbicki A, Vachiery JL, Barbera JA, Beghetti M, Corris P, Gaine S, Gibbs JS, Gomez-Sanchez MA, Jondeau G, Klepetko W, Opitz C, Peacock A, Rubin L, Zellweger M, Simonneau G; ESC Committee for Practice Guidelines (CPG), Vahanian A, Auricchio A, Bax J, Ceconi C, Dean V, Filippatos G, Funck-Brentano C, Hobbs R, Kearney P, McDonagh T, McGregor K, Popescu BA, Reiner Z, Sechtem U, Sirnes PA, Tendera M, Vardas P, Widimsky P; Document Reviewers, Sechtem U, Al Attar N, Andreotti F, Aschermann M, Asteggiano R, Benza R, Berger R, Bonnet D, Delcroix M, Howard L, Kitsiou AN, Lang I, Maggioni A, Nielsen-Kudsk JE, Park M, Perrone-Filardi P, Price S, Domenech MT, Vonk-Noordegraaf A, Zamorano JL (2009) Guidelines for the diagnosis and treatment of pulmonary hypertension: The Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS), endorsed by the International Society of Heart and Lung Transplantation (ISHLT). Eur Heart J 30:2493–2537

  14. Gabbay E, Yeow W, Playford D (2007) Pulmonary arterial hypertension (PAH) is an uncommon cause of pulmonary hypertension (PH) in an unselected population: the Armadale echocardiography study. Am J Resp Crit Care Med 175:A713

    Google Scholar 

  15. Simonneau G, Robbins IM, Beghetti M, Channick RN, Delcroix M, Denton CP, Elliott CG, Gaine SP, Gladwin MT, Jing ZC, Krowka MJ, Langleben D, Nakanishi N, Souza R (2009) Updated clinical classification of pulmonary hypertension. J Am Coll Cardiol 54:S43–S54

    PubMed  Article  Google Scholar 

  16. Widera C, Horn-Wichmann R, Kempf T, Bethmann K, Fiedler B, Sharma S, Lichtinghagen R, Leitolf H, Ivandic B, Katus HA, Giannitsis E, Wollert KC (2009) Circulating concentrations of follistatin-like 1 in healthy individuals and patients with acute coronary syndrome as assessed by an immunoluminometric sandwich assay. Clin Chem 55:1794–1800

    PubMed  Article  CAS  Google Scholar 

  17. Honold J, Geiger L, Assmus B, Fischer-Rasokat U, Schaechinger V, Zeiher AM, Spyridopoulos I (2008) The initial slope of the VCO2/VO2-curve (s1) in cardiopulmonary exercise testing is a strong and independent predictor of outcome in patients with previous myocardial infarction. Clin Res Cardiol 97:882–890

    PubMed  Article  Google Scholar 

  18. Okawa-Takatsuji M, Aotsuka S, Fujinami M, Uwatoko S, Kinoshita M, Sumiya M (1999) Up-regulation of intercellular adhesion molecule-1 (ICAM-1), endothelial leucocyte adhesion molecule-1 (ELAM-1) and class II MHC molecules on pulmonary artery endothelial cells by antibodies against U1-ribonucleoprotein. Clin Exp Immunol 116:174–180

    PubMed  Article  CAS  Google Scholar 

  19. Sanchez O, Marcos E, Perros F, Fadel E, Tu L, Humbert M et al (2007) Role of endothelium-derived CC chemokine ligand 2 in idiopathic pulmonary arterial hypertension. Am J Respir Crit Care Med 176:1041–1047

    PubMed  Article  CAS  Google Scholar 

  20. Blanco-Colio LM, Martín-Ventura JL, Muñóz-García B, Orbe J, Páramo JA, Michel JB, Ortiz A, Meilhac O, Egido J (2007) Identification of soluble tumor necrosis factor-like weak inducer of apoptosis (sTWEAK) as a possible biomarker of subclinical atherosclerosis. Arterioscler Thromb Vasc Biol 27:916–922

    PubMed  Article  CAS  Google Scholar 

  21. Kralisch S, Ziegelmeier M, Bachmann A, Seeger J, Lössner U, Blüher M, Stumvoll M, Fasshauer M (2008) Serum levels of the atherosclerosis biomarker sTWEAK are decreased in type 2 diabetes and end-stage renal disease. Atherosclerosis 199:440–444

    PubMed  Article  CAS  Google Scholar 

  22. Maecker H, Varfolomeev E, Kischkel F, Lawrence D, Le Blanc H, Lee W, Hurst S, Danilenko D, Li J, Filvaroff E, Yang B, Daniel D, Ashkenazi A (2005) TWEAK attenuates the transition from innate to adaptive immunity. Cell 123:931–944

    PubMed  Article  CAS  Google Scholar 

  23. Moreno JA, Muñoz-García B, Martín-Ventura JL, Madrigal-Matute J, Orbe J, Páramo JA, Ortega L, Egido J, Blanco-Colio LM (2009) The CD163-expressing macrophages recognize and internalize TWEAK: potential consequences in atherosclerosis. Atherosclerosis 207:103–110

    PubMed  Article  CAS  Google Scholar 

Download references

Conflict of interest

Arthur Filusch, Thomas Zelniker, Christian Baumgärtner, Sabine Eschricht, Norbert Frey, Hugo A Katus, and Emmanuel Chorianopoulos have no conflict of interest

Author information

Affiliations

  1. Department of Cardiology, Angiology and Pulmology, Heidelberg University Hospital, Im Neuenheimer Feld 410, 69120, Heidelberg, Germany

    Arthur Filusch, Thomas Zelniker, Christian Baumgärtner, Sabine Eschricht, Hugo A. Katus & Emmanuel Chorianopoulos

  2. Department of Cardiology and Angiology, Kiel University Hospital, Schittenhelmstr. 12, 24105, Kiel, Germany

    Norbert Frey

Authors
  1. Arthur Filusch
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Thomas Zelniker
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Christian Baumgärtner
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Sabine Eschricht
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Norbert Frey
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Hugo A. Katus
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Emmanuel Chorianopoulos
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emmanuel Chorianopoulos.

Electronic supplementary material

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Filusch, A., Zelniker, T., Baumgärtner, C. et al. Soluble TWEAK predicts hemodynamic impairment and functional capacity in patients with pulmonary arterial hypertension. Clin Res Cardiol 100, 879–885 (2011). https://doi.org/10.1007/s00392-011-0318-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00392-011-0318-z

Keywords

  • Exercise capacity
  • sTWEAK
  • Pulmonary artery hypertension
  • Hemodynamics